Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDCO-157 · 1 trial · 1 indication
To evaluate the dose-response of MDCO-157 (at 3 doses) compared to Plavix (300 mg), using Emax and AUEC with VASP, over 24 hours: * Maximum effect of P2Y12 receptor inhibition (Emax) using VASP (flow cytometry) * Area under the effect of P2Y12 receptor inhibition time curve (AUEC) using VASP (flow cytometry)
| Arm | Type | Description |
|---|---|---|
| 75mg MDCO-157 | ACTIVE_COMPARATOR | iv |
| 150mg MDCO-157 | ACTIVE_COMPARATOR | iv |
| 300mg MDCO-157 | ACTIVE_COMPARATOR | iv |
| 300mg PLAVIX | ACTIVE_COMPARATOR | oral |
| Name | Type | Description |
|---|---|---|
| MDCO-157 | DRUG | intravenous administration |
| PLAVIX | DRUG | oral administration |
Inclusion Criteria * Healthy males or females 18 to 45 years of age, inclusive. * Provide written informed consent for genetic testing and written informed consent for the study before initiation of any study related procedures * Affiliated to the French social security system * Screening and basel...
MDCO-157 is an investigational small molecule drug developed by Novartis AG (ticker NVS). It has been studied in a Phase 1 clinical trial in healthy volunteers to evaluate its pharmacokinetics and pharmacodynamics. The specific therapeutic indication for MDCO-157 has not been disclosed.
MDCO-157 is being developed by Novartis AG, which trades under the ticker symbol NVS. Novartis is a multinational pharmaceutical company. The drug is currently in Phase 1 clinical development.
MDCO-157 is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are no active trials at this time. The completed trial enrolled 37 healthy volunteers.
MDCO-157 has been evaluated in a single Phase 1 clinical trial, NCT01860105, titled "Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation." The trial was completed, enrolled 37 participants, and was conducted in France.
The molecular target of MDCO-157 has not been disclosed. It is a small molecule drug, but no specific target or mechanism of action information is available.